Skip to main content

Education/ACR/EULAR

Dr. John Cush
@RheumNow
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. https://t.co/br5LBqkqeu
Dr. John Cush
@RheumNow
Conducting a CAR-T Trial: A Pediatric Rheumatologist’s Reflections At #ACR26, a scientific session titled “Program and Ethical Readiness in Pediatric Rheumatology: Building CAR Therapy Pathways for Rare Disease Care” addressed our readiness as a field for CAR-based therapies. https://t.co/qYWKJtTxmZ
Dr. John Cush
@RheumNow
Top 6 Practice-Changing Highlights from ACR26 The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance. Here is our https://t.co/JmRpPh8Wzi
Dr. John Cush
@RheumNow
Two Prescriptions, One Patient Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Dr. John Cush
@RheumNow
AI vs Rheumatologist? The Better Answer May Be Both Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo
Dr. John Cush
@RheumNow
Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt
Dr. John Cush
@RheumNow
All RA-ILD deserves a trial of immunomodulation The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment https://t.co/vxr8NDruGI
anita
@docdhanrajani
Final #ACR2026 post (maybe? 😄)! Huge shoutout to @RheumNow and the incredible team for their phenomenal work in rheumatology education! Can’t believe it took me this long to collaborate with them, but I have a feeling this is the beginning of a long-term relationship! 🙌
×